Increased activity of the receptor-associated tyrosine kinase JAK2 by activating mutation (most frequently JAK2V617F) is a feature of this group of MPN, including essential thrombocythaemia (ET), Polycythaemia Vera (PV) and Primary Myelofibrosis (PMF)3. Here, JAK2 is linked to acquired polycythemia vera.